AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
Janssen taps wearable tech in Invokana heart failure trialJanssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world Share XJanssen taps wearable tech in Invokana heart failure trialhttps://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
AZ’s Farxiga gets FDA Fast Track for heart failureThe FDA has fast-tracked AstraZeneca’s Farxiga (dapagliflozin) as a treatment to reduce risk of cardiovascular death, or worsening Share XAZ’s Farxiga gets FDA Fast Track for heart failurehttps://pharmaphorum.com/news/azs-farxiga-gets-fda-fast-track-for-heart-failure/
Despite trial miss, Novartis still believes in Entresto for HFpEFNovartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction Share XDespite trial miss, Novartis still believes in Entresto for HFpEFhttps://pharmaphorum.com/news/despite-trial-miss-novartis-still-believes-in-entresto-for-hfpef/
AZ’s Farxiga first in class to improve outcomes in heart failureAstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class Share XAZ’s Farxiga first in class to improve outcomes in heart failurehttps://pharmaphorum.com/news/azs-farxiga-first-in-class-to-improve-outcomes-in-heart-failure/
Novartis’ heart failure drug misses expanded use trial targetNovartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped Share XNovartis’ heart failure drug misses expanded use trial targethttps://pharmaphorum.com/news/novartis-heart-failure-drug-misses-expanded-use-trial-target/
